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Abstract
Background: To investigate the effect of oxidized low density lipoprotein receptor-1 (LOX-1) on tubular epithelial-
mesenchymal transition (TEMT) induced by oxidized low-density lipoprotein (ox-LDL) and its mechanism.
Methods: NRK-52E cells were incubated with ox-LDL (0, 25, 50, and 100 μg/ml) for 24 hours or pre-treated with
the chemical inhibitor of the LOX-1 receptor polyinosinic acid (poly I) and carrageenan or the antioxidant N-acetyl-
L-cysteine (NAC), the cells were then exposed to 50 μg/ml of ox-LDL.The expression of LOX-I, E-cadherin, a-smooth
muscle actin (a-SMA) and reactive oxygen species (ROS) were analyzed by real-time PCR, western blotting analysis,
immunofluorescence and confocal laser scanning microscopy.
Results: Ox-LDL increased the expression of LOX-1 mRNA and protein in a dose-dependent manner from 0 to 100
μg/ml (P < 0.05). Following the increase in the LOX-1 protein level, the lipid intake, ROS generation and a-SMA
expression increased; however, the E-cadherin level decreased. The pre-treatment with poly I or carrageenan or
NAC significantly inhibited the LOX-1 expression, a-SMA expression, the lipid intake and ROS generation and
reversed decrease of E-cadherin expression induced by ox-LDL. Meanwhile, the ROS generation were associated
with a increase in the LOX-1 expression. The a-SMA expression was positively correlated with the ROS generation
and LOX-1 expression, and the E-cadherin expression was negatively correlated with the ROS generation and
LOX-1 expression.
Conclusions: LOX-1 and ROS may play a important role in epithelial-mesenchymal transition of NRK52E induced
by OX-LDL.
Introduction
Several studies have revealed that anoxia, ischemia and
many cytokines can induce the tubular TEMT. Stephanie
et al reported that a short-term diet of high cholesterol
c o u l di n d u c ear i s ei no x i d a t i v es t r e s sa n dt h a to x - L D L
could induce the activation of different intercellular cyto-
kines among the interstitial tubular epithelial cells and
alter the expression of certain genes, which leads to renal
tubular interstitial fibrosis[1]. However, there are few
reports regarding the TEMT induced by ox-LDL, and
whether ROS is involved remains unknown. LOX-1 was
recently found to be one of the ox-LDL receptors
expressed in many cells. It is involved not only in the
cellular interaction and adhesion, signal transduction and
mediation of the digestion and degradation of ox-LDL
but also in many pathological processes, including ische-
mia-reperfusion injured myocardium, atherosclerosis,
rheumatoid arthritis (RA) and kidney injury of diabetic
nephropathy. Currently, there is some controversy as to
whether the LOX-1 is expressed in the tubular epithelial
cells. This study investigates the effects of the lectin-like
oxidized low density lipoprotein receptor-1 (LOX-1) in
TEMT induced by ox-LDL and its mechanism.
Materials and methods
Main reagents
FBS and DMEM (Gibco, USA), NRK-52E (ATCC, USA),
anti-rat LOX-1 goat antibody (Santa Cruz Biotechnol-
ogy, USA), b-actin (Santa Cruz Biotechnology, USA),
anti-rat mouse E-cadherin monoclonal antibody (BD,
* Correspondence: ghxding@gmail.com
Division of Nephrology, Renmin Hospital of Wuhan University, Wuhan
430060, China
Wang et al. Lipids in Health and Disease 2010, 9:120
http://www.lipidworld.com/content/9/1/120
© 2010 Wang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.USA), and mouse a-SMA monoclonal antibody (Boster,
P.R.China) were purchased from the corporations given.
The N-acetylcysteine (NAC), Oil Red O, polyinosinic I
(Poly I), carrageenan (Sigma, USA), the fluorescent
probe CM-H
2DCFDA (Molecular Probes, USA), and
Trizol (Invitrogen, USA) were purchased from the cor-
porations shown. A chemiluminescent kit (Santa Cruz
Biotechnology, USA) was purchased, and the LOX-1 pri-
mers and fluorescent probes were synthesized by Da an
Gene in China. The SuperScript™ First-Strand reaction
synthesis system kit was purchased from Fermentas,
USA, and the SYBR Green PCR Master Mix was pur-
chased from ABI, USA.
Preparation of oxidized low density lipoprotein (ox-LDL)
The native LDL (n-LDL) was prepared by a one-step den-
sity gradient ultracentrifugation and determined by the
Lowry method. The n-LDL was incubated in a 5 μmol/L
Cu
2+ solution for 24 hours at 37°C, and then placed in
PBS with 200 μmol/ml EDTA at 4°C for 24 hours for dia-
lysis. Subsequently, it was sterilized by a 0.45 μmm i c r o -
filter and stored at 4°C in the dark. The modification level
was determined by the thiobarbituric acid (TBA) test.
Cell culture of NRK-52E and grouping
NRK-52E were cultured in DMEM medium with 5%
newborn calf serum, 100 IU/ml penicillin, 100 μg/ml
streptomycin in 5% CO2 at 37°C,Cells were incubated
for 24 hours with 0.5% newborn calf serum before ox-
LDL stimulation.
Grouping for each experiment:
1. Group of different doses of ox-LDL: different con-
centrations of ox-LDL (0, 25, 50 and 100 μg/ml) were
added into the medium for incubation for 24 hours;
2. Group of Lox-1 inhibitors: samples were pretreated
with Poly I (250 μg/ml) or carrageenan (250 μg/ml) or
NAC for incubation for 2 hours, and then ox-LDL was
a d d e da tt h ef i n a lc o n c e n t r a t i o no f5 0μg/ml in the ox-
LDL medium for 24 hours.
Real-time PCR for the Detection of the LOX-1 mRNA Level
Trizol was applied to extract the total RNA, and reverse
transcription was conducted in a 20 μl reaction system.
Using an UNO II PCR machine, quantitative fluorescent
PCR was performed under the following conditions:
The temperature was 95°C for 5 min, 94°C for 20 s, 57°C
for 20 s, 72°C for 20 s, 72°C for 5 min, and 55°C for 10 s;
55 cycles were used. The 18S RNA was used for internal
control. The primers were designed and synthesized as fol-
lows: primers LOX-1 forward: 5’-GCCTAGTGTTATC
AGTGACC-3’, anti-sense 3’-CTTAGTTTCTCCCTTG
ACTTC-5’;a n d1 8 Ss e n s e :5 ’-CCGAGAAGTTTCAGCAC
ATCC-3’,a n t i - s e n s e :5 ’-TGGCAGTGATAGCGAAGG
CT-3’.
Western blotting for the detection of LOX-1, a-SMA and
E-cadherin
The cells were lysed by a 4°C pretreated cell lysis solu-
tion, and the total protein level was determined by the
Comas blue method. The samples with 30 μgt o t a l
protein each were applied for SDS-PAGE and were elec-
tro-transferred to the NC membrane. In addition, 5%
lipid-free milk powder was used for blocking for 2 hours.
The anti-rat goat LOX-1 (1:200), a-SMA(1:100) and anti-
E-cadherin antibody (1:600) were added separately, and
the membrane was incubated at 4°C overnight. After
washing, the anti-goat and anti-rabbit IgG antibody linked
with HRP were added for incubation for 1 hour, and the
exposed film was later developed. Using b-actin as the
internal control, the relative protein expression levels
were determined quantitatively using an imaging analyzing
system to scan the absorbance of specific bands.
Oil Red O Staining
The cell cover slides were washed with PBS three times
for 5 minutes each and fixed with 50% isopropanol for 1
minute.Cell were stained 10 minutes with Oil Red O
and then washed with distilled water. Hematoxylin was
applied for 5 minutes for staining, and the images were
collected by a PIAS-1000 imaging analysis system after
color separation.
Confocal Laser for the Detection of the Intracellular ROS
Level
Intracellular ROS was labeled with CM-H
2DCFDA,
which is a fluorescent probe. The CM-H
2DCFDA sto-
rage solution was diluted to 10 μM by PBS with 2% glu-
cose before usage. The medium was discarded, and the
cell cover slides were added with 0.5 ml CM-H
2DCFDA
for incubation for 45 minutes in the dark. Then confocal
laser scanning was performed, and the results were ana-
lyzed by the Leica Confocal Software.
Statistics
Data were analyzed by SPSS 11.0 software, and the one-
way analysis of variance (ANOVA) was applied for
inter-group comparison. The LSD test was applied for
the one-to-one comparison, and the Pearson’s test was
applied for the correlation analysis. P < 0.05 was consid-
ered significant.
Results
The influence of ox-LDL, LOX-1 inhibitor and NAC on the
LOX-1 mRNA and protein levels
Low levels of LOX-1 mRNA and protein are expressed in
normal NRK52E cells. In this study, the different concen-
trations of ox-LDL significantly enhanced the expression
levels of LOX-1 mRNA and protein in a dose-dependent
manner, with concentrations ranging from 0 to 100 μg/
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treated with poly I, carrageenan or NAC showed signifi-
cant repression of the upregulated LOX-1 mRNA and
protein levels induced by the ox-LDL (Figures 1).
The influence of Ox-LDL, LOX-1 inhibitor and NAC
stimulant on the intracellular Lipids
In normal NRK52E cells, a few lipid drops stained with
oil red O could be observed, and with the treatment of
incremental concentrations of ox-LDL, the intracellular
red oil O stained lipids increased. Meanwhile, the sam-
ples pretreated with poly I, carrageenan or NAC signifi-
cantly reduced the red oil O stained lipids upon
upregulation by the ox-LDL.
The influence of Ox-LDL, LOX-1 inhibitor or NAC on the
intracellular ROS
No ROS were observed in the normal NRK52E cells;
with the treatment of incremental concentrations of the
ox-LDL stimulant, the expressions of LOX-1 and intra-
cellular ROS increased. The samples treated with poly I
or carrageenan revealed suppressed LOX-1 mRNA and
protein expression induced by the ox-LDL; as a result,
the intracellular ROS was reduced. When the NAC was
applied to suppress the ROS generation, the LOX-1
expression was reduced accordingly. This suggests that
the generation of ROS has a positive correlation with
the LOX-1 expression, and the correlation coefficient (r)
was found to be 0.91 (Figures 2).
The influence of Ox-LDL, LOX-1 Inhibitor and NAC on
NRK52E Cell Transdifferentiation
Little a-SMA expression was observed in the normal
NRK52K cells; however, high levels of E-cadherin pro-
tein were observed. With the incremental LOX-1
expression and ROS, the a-SMA was increasingly
expressed and was accompanied with a reduction of E-
cadherin, the cells began transdifferentiation. The sam-
ples pretreated with poly I or carrageenan to block the
LOX-1 or with NAC to suppress the ROS exhibited
reduced a-SMA expression but increased E-cadherin
expression. The a-SMA exhibited a close positive corre-
lation with the LOX-1 and ROS, and the correlation
coefficients were found to be 0.97 and 0.87, respectively.
Meanwhile, the E-cadherin exhibited a close negative
correlation with the LOX-1 and ROS, and the correla-
tion coefficients were found to be -0.94 and -0.82,
respectively (see Figures 3 and 4).
Discussion
It is well-recognized that dyslipidemia can cause or wor-
sen renal injuries including glomerulus, tubule and
tubule-interstitial injuries, which display with tubular
epithelial cell hypertrophy, inflammatory cell infiltration,
cytokine generation and tubular interstitial fibrosis [2,3],
but the mechanism is unclear.
LOX-1 is a recently discovered specific ox-LDL recep-
tor that is found to be expressed in many kinds of cells to
mediate multiple pathological injuries,such as ischemia-
reperfusion,injured myocardium, atherosclerosis, rheu-
matoid arthritis. Applying an anti-LOX-1 treatment can
reverse those pathological injuries. It is possible that
LOX-1 could be a new target for the treatment of multi-
ple diseases [4-8]. A few studies on LOX-1 expression in
t h ek i d n e yh a v es u g g e s t e dt h a tL O X - 1m i g h th a v ea n
effect on the development of chronic renal disease by the
evidence that anti-LOX-1 treatment can reverse enlarged
kidney, oxidative stress, and leukocyte infiltration; can
lower the level and function of mitochondria enzymes
caused by diabetes; and can protect the renal microvascu-
lar bed [9-13]. However, it is still under debate whether
LOX-1 is expressed in the tubular epithelial cells. By
applying real-time PCR and western blot, our study
showed that there is LOX-1 mRNA transcription and
p r o t e i ne x p r e s s i o ni nn o r m a l NRK52E cells, confirming
the reports by Jesus et al [10]. Furthermore, by using dif-
ferent concentrations of ox-LDL to stimulate the
NRK52E cells, our study reveals that ox-LDL can up-reg-
ulate the mRNA and protein levels of LOX-1, and within
the range of 0 to 100 μg/ml, the ox-LDL stimulates the
LOX-1 expression in a dose-dependent manner.
Tubular EMT is the major mechanism in the develop-
ment of tubular interstitial fibrosis, and it exhibits a loss
of tubular polarity, the expression of a-SMA and vimen-
tin (markers of mesenchymal cells) and the loss of E-cad-
herin and cytokeratin (markers of epithelial cells). Our
study revealed that the ox-LDL stimulates the expression
of a-SMA and the reduction of E-cadherin. Within the
range from 0 up to 100 μg/ml, the increasing concentra-
tion of ox-LDL leads to higher a-SMA expression and
lower levels of E-cadherin, suggesting that the ox-LDL
enhances the TEMT of NRK52E in a dose-dependent
manner. The cells pretreated with the LOX-1 inhibitor
poly I and carrageenan, which suppressed the expression
of the LOX-1, exhibited a reduction in the a-SMA
expression and an increase in the E-cadherin expression.
This suggested that the a-SMA has a positive correlation
with LOX-1 and that E-cadherin has a negative correla-
tion with LOX-1. Our study confirms that the ox-LDL
induces the tubular TEMT through LOX-1.
ROS is usually considered to be a toxic by-product of
cell metabolism. It interacts with lipids, proteins or
DNA, leading to histological changes and cellular mal-
function; furthermore, this reaction is different in differ-
ent cells. During the process of renal fibrosis, ROS plays
an important role in the synthesis and degradation of
the extracellular matrix of the glomerulus and tubular
interstitial tissue. It has also been reported that ROS is
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pathway, in the tubular TEMT induced by TGF-b and
aldosterone [14-16]. However, there are still no reports
on whether the ox-LDL induces TEMT through ROS.
Our study shows that the ox-LDL enhances the lipid
intake and ROS generation, and the lipid intake reduces
with the reduction of ROS after the inhibition of the
LOX-1 expression by poly I and carrageenan. This sug-
gests that the ox-LDL binds the LOX-1 to induce lipid
intake, thus leading to the ROS generation. Meanwhile,
after pretreatment with the antioxidant NAC and incu-
bation with the ox-LDL, the cells exhibit partially
reversed a-SMA expression up-regulated by the ox-LDL
and E-cadherin expression down-regulated by the ox-
LDL, thus suggesting ROS is one of the mechanisms of
TEMT of NRK52E induced by ox-LDL. In addition, the
expression of LOX-1 was impaired after the inhibition
of ROS by NAC; this suggests that the ROS is not only
the product of a combination of ox-LDL and LOX-1 but
also the stimulant of the LOX-1 expression, where they
act as positive feedback for each other.
In summary, ox-LDL enhances the LOX-1 expression
in tubular epithelial cells in a dose-dependent manner
within a certain concentration range. Ox-LDL binds to
Figure 1 The influence of ox-LDL, LOX-1 inhibitor and NAC on the LOX-1 mRNA and protein levels. A: The expression of LOX-1mRNA. Within
the range of 0-100 μg/ml, the ox-LDL enhances the LOX-1 mRNA transcription in NRK52E cells in a dose-dependent manner. The LOX-1 inhibitor poly
I and carrageenan and the antioxidant NAC can suppress the LOX-1 mRNA transcription induced by ox-LDL in NRK52E cells. B: The expression of the
LOX-1 protein. Within the range of 0-100 μg/ml ox-LDL enhances the LOX-1 protein expression in NRK52E cells in a dose-dependent manner. The
LOX-1 inhibitor poly I and carrageenan and the antioxidant NAC can suppress the LOX-1 protein expression induced by ox-LDL in NRK52E cells. Note:
1: 0 μg/ml ox-LDL; 2: 25 μg/ml ox-LDL; 3: 50 μg/ml ox-LDL; 4: 100 μg/ml ox-LDL; 5: poly I + 50 μg/ml ox-LDL; 6: carrageenan + 50 μg/ml ox-LDL; 7:
NAC + 50 μg/ml ox-LDL; comparison with 0 μg/ml ox-LDL,
aP < 0.05; comparison with 50 μg/ml ox-LDL,
bP <0 . 0 5 .
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the LOX-1 inhibitors including poly I and carrageenan and the antioxidant NAC prohibit the ROS generation induced by ox-LDL in NRK52E cells.
Note: 1: 0 μg/ml ox-LDL; 2: 25 μg/ml ox-LDL; 3: 50 μg/ml ox-LDL; 4: 100 μg/ml ox-LDL; 5: poly I + 50 μg/ml ox-LDL; 6: carrageenan + 50 μg/ml
ox-LDL; 7: NAC + 50 μg/ml ox-LDL; compared with the 0 μg/ml ox-LDL group,
aP < 0.05; compared with the 50 μg/ml ox-LDL group,
bP < 0.05.
Figure 3 The expression of a-SMA. Within the range of 0-100 μg/ml, the ox-LDL stimulates the a-SMA expression in NRK52E cells in a dose-
dependent manner, while the LOX-1 inhibitors including poly I and carrageenan and the antioxidant NAC suppress the expression of a-SMA
induced by ox-LDL in NRK52E cells. Note: 1: 0 μg/ml ox-LDL; 2: 25 μg/ml ox-LDL; 3: 50 μg/ml ox-LDL; 4: 100 μg/ml ox-LDL; 5: poly I + 50 μg/ml
ox-LDL; 6: carrageenan + 50 μg/ml ox-LDL; 7: NAC + 50 μg/ml ox-LDL.
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ROS generation and TEMT of NRK52E through ROS.
In addition, as a positive feedback, the ROS upregulates
the LOX-1 expression and is thus involved in the
TEMT of NRK52E. The suppression of LOX-1 can inhi-
bit the ROS generation and TEMT of NRK52E to pro-
tect the normal tubular morphology.
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